Hi-Tech Pharmacal Ups R&D Spending At Expense Of Earnings
This article was originally published in The Tan Sheet
Hi-Tech Pharmacal nearly doubled its research and development spending in its second fiscal quarter as the firm worked on Rx and OTC generic versions of a number of branded drug products
You may also be interested in...
Hi-Tech Pharmacal plans to build up its Health Care Products Division through a two-pronged approach involving launching new products aimed at diabetics and expanding distribution channels
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning